David Hoang
Stock Analyst at Deutsche Bank
(4.80)
# 512
Out of 4,683 analysts
127
Total ratings
65.9%
Success rate
36.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintained: Buy | $287 → $300 | $249.29 | +20.34% | 8 | Aug 26, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $135 → $127 | $93.61 | +35.68% | 5 | Aug 26, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintained: Buy | $37 → $38 | $29.58 | +28.47% | 11 | Aug 25, 2026 | |
| NBIX Neurocrine Biosciences | Rated: Hold | $190 → $165 | $156.59 | +5.37% | 12 | Aug 13, 2026 | |
| ATAI AtaiBeckley | Downgraded: Hold | $12 → $8 | $7.39 | +8.25% | 2 | Aug 12, 2026 | |
| HRMY Harmony Biosciences Holdings | Rated: Hold | $36 → $39 | $39.66 | -1.66% | 8 | Aug 5, 2026 | |
| KYMR Kymera Therapeutics | Initiated Coverage: Hold | $120 | $125.55 | -4.42% | 1 | Jul 29, 2026 | |
| DNLI Denali Therapeutics | Rated: Buy | $31 → $35 | $24.57 | +42.45% | 10 | Jul 16, 2026 | |
| BHVN Biohaven | Rated: Buy | $65 → $20 | $16.95 | +17.99% | 2 | Jun 26, 2026 | |
| APGE Apogee Therapeutics | Downgraded: Hold | $118 → $135 | $134.95 | +0.04% | 4 | Jun 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $420 → $374 | $377.37 | -0.89% | 9 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $281 → $280 | $207.15 | +35.17% | 9 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $12 → $14 | $19.46 | -28.06% | 23 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 → $90 | $63.79 | +41.09% | 9 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 → $45 | $49.16 | -8.46% | 3 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $7 | $2.99 | n/a | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $9.72 | n/a | 3 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $3.46 | n/a | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $220 | $239.00 | n/a | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $80 | $89.12 | n/a | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $24 → $3 | $0.1739 | n/a | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 | $0.6153 | n/a | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $73 | $359.76 | n/a | 1 | Mar 12, 2020 |
Jazz Pharmaceuticals
Aug 26, 2026
Maintained: Buy
Price Target: $287 → $300
Current: $249.29
Upside: +20.34%
Spyre Therapeutics
Aug 26, 2026
Maintained: Buy
Price Target: $135 → $127
Current: $93.61
Upside: +35.68%
ACADIA Pharmaceuticals
Aug 25, 2026
Maintained: Buy
Price Target: $37 → $38
Current: $29.58
Upside: +28.47%
Neurocrine Biosciences
Aug 13, 2026
Rated: Hold
Price Target: $190 → $165
Current: $156.59
Upside: +5.37%
AtaiBeckley
Aug 12, 2026
Downgraded: Hold
Price Target: $12 → $8
Current: $7.39
Upside: +8.25%
Harmony Biosciences Holdings
Aug 5, 2026
Rated: Hold
Price Target: $36 → $39
Current: $39.66
Upside: -1.66%
Kymera Therapeutics
Jul 29, 2026
Initiated Coverage: Hold
Price Target: $120
Current: $125.55
Upside: -4.42%
Denali Therapeutics
Jul 16, 2026
Rated: Buy
Price Target: $31 → $35
Current: $24.57
Upside: +42.45%
Biohaven
Jun 26, 2026
Rated: Buy
Price Target: $65 → $20
Current: $16.95
Upside: +17.99%
Apogee Therapeutics
Jun 23, 2026
Downgraded: Hold
Price Target: $118 → $135
Current: $134.95
Upside: +0.04%
Jun 2, 2026
Maintained: Buy
Price Target: $420 → $374
Current: $377.37
Upside: -0.89%
May 5, 2026
Rated: Buy
Price Target: $281 → $280
Current: $207.15
Upside: +35.17%
Mar 26, 2026
Maintained: Sell
Price Target: $12 → $14
Current: $19.46
Upside: -28.06%
Mar 10, 2026
Maintained: Buy
Price Target: $60 → $90
Current: $63.79
Upside: +41.09%
Nov 13, 2025
Maintained: Buy
Price Target: $52 → $45
Current: $49.16
Upside: -8.46%
Jul 25, 2024
Initiated Coverage: Buy
Price Target: $7
Current: $2.99
Upside: n/a
Jul 17, 2024
Maintained: Buy
Price Target: $16
Current: $9.72
Upside: n/a
Mar 6, 2024
Maintained: Buy
Price Target: $16
Current: $3.46
Upside: n/a
Apr 26, 2023
Initiated Coverage: Hold
Price Target: $220
Current: $239.00
Upside: n/a
Apr 26, 2023
Initiated Coverage: Buy
Price Target: $80
Current: $89.12
Upside: n/a
Dec 7, 2022
Downgraded: Hold
Price Target: $24 → $3
Current: $0.1739
Upside: n/a
Sep 30, 2020
Maintained: Buy
Price Target: $19
Current: $0.6153
Upside: n/a
Mar 12, 2020
Initiated Coverage: Buy
Price Target: $73
Current: $359.76
Upside: n/a